文献速递物质与行为成瘾

辅助氯胺酮联合基于预防复发的心理治疗用于酒精使用障碍的治疗

Adjunctive Ketamine With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder.
PubMed 文献 · Am J Psychiatry · 2022-01-11

这项双盲安慰剂对照2期试验将96例重度酒精使用障碍患者随机分配至氯胺酮或生理盐水输注联合心理治疗或酒精教育四种条件,主要结局为6个月随访时自报戒酒天数百分比和确认的酒精复发。氯胺酮组戒酒天数显著多于安慰剂组(平均差=10.1%,95%CI=1.1,19.0),氯胺酮联合治疗组较生理盐水联合教育组减少最多(15.9%,95%CI=3.8,28.1),两组复发率无显著差异。

要点

  • 氯胺酮组6个月随访戒酒天数显著多于安慰剂组(平均差=10.1%,95%CI=1.1,19.0)。
  • 氯胺酮联合心理治疗组较生理盐水联合酒精教育组戒酒天数改善最大(15.9%,95%CI=3.8,28.1)。
  • 氯胺酮与安慰剂组复发率无显著差异;治疗耐受良好,无与研究药物相关的严重不良事件。

核心结论

  • 三次氯胺酮输注在酒精使用障碍患者中耐受良好,且与6个月随访时更多戒酒天数相关。
  • 研究结果提示在氯胺酮治疗基础上联合心理治疗可能具有有益效应。

研究设计与样本

  • 双盲安慰剂对照2期临床试验,96例重度酒精使用障碍患者随机分配至四种条件之一。
  • 四种条件为:三次每周氯胺酮输注(0.8 mg/kg静脉输注40分钟)联合心理治疗、三次生理盐水输注联合心理治疗、三次氯胺酮输注联合酒精教育、三次生理盐水输注联合酒精教育。
  • 主要结局为6个月随访时自报戒酒天数百分比和确认的酒精复发。
  • 96例参与者(35名女性;平均年龄44.07岁[SD=10.59])纳入意向性治疗分析。

主要发现

  • 氯胺酮组6个月随访时戒酒天数显著多于安慰剂组(平均差=10.1%,95%CI=1.1,19.0),但置信区间较宽。
  • 氯胺酮联合心理治疗组较生理盐水联合酒精教育组戒酒天数改善最大(15.9%,95%CI=3.8,28.1)。
  • 氯胺酮组与安慰剂组复发率无显著差异。
  • 治疗耐受良好,无与研究药物相关的严重不良事件。

局限性

  • 置信区间较宽,符合概念验证性研究的特点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Early evidence suggests that ketamine may be an effective treatment to sustain abstinence from alcohol. The authors investigated the safety and efficacy of ketamine compared with placebo in increasing abstinence in patients with alcohol use disorder. An additional aim was to pilot ketamine combined with mindfulness-based relapse prevention therapy compared with ketamine and alcohol education as a therapy control. METHODS: In a double-blind placebo-controlled phase 2 clinical trial, 96 patients with severe alcohol use disorder were randomly assigned to one of four conditions: 1) three weekly ketamine infusions (0.8 mg/kg i.v. over 40 minutes) plus psychological therapy, 2) three saline infusions plus psychological therapy, 3) three ketamine infusions plus alcohol education, or 4) three saline infusions plus alcohol education. The primary outcomes were self-reported percentage of days abstinent and confirmed alcohol relapse at 6-month follow-up. RESULTS: Ninety-six participants (35 women; mean age, 44.07 years [SD=10.59]) were included in the intention-to-treat analysis. The treatment was well tolerated, and no serious adverse events were associated with the study drug. Although confidence intervals were wide, consistent with a proof-of-concept study, there were a significantly greater number of days abstinent from alcohol in the ketamine group compared with the placebo group at 6-month follow-up (mean difference=10.1%, 95% CI=1.1, 19.0), with the greatest reduction in the ketamine plus therapy group compared with the saline plus education group (15.9%, 95% CI=3.8, 28.1). There was no significant difference in relapse rate between the ketamine and placebo groups. CONCLUSIONS: This study demonstrated that treatment with three infusions of ketamine was well tolerated in patients with alcohol use disorder and was associated with more days of abstinence from alcohol at 6-month follow-up. The findings suggest a possible beneficial effect of adding psychological therapy alongside ketamine treatment.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Grabski M, McAndrew A, Lawn W, et al. Adjunctive Ketamine With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder. Am J Psychiatry. 2022. PMID: 35012326. doi:10.1176/appi.ajp.2021.21030277

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。